Frontiers in oncology · 2026
Subclinical pulmonary embolism in first-line/induction therapy of lung cancer - a remaining clinically relevant adverse event.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mersmann Kristin, Metzenmacher Martin, Zaun Gregor, Wiesweg Marcel, Oezkan Filiz, Winantea Jane, Taube Christian, Theegarten Dirk, Schuler Martin, Umutlu Lale, Bölükbas Servet, Doerr Fabian, Messiha Daniel, Opitz Marcel, Eberhardt Wilfried Ee, Wienker Johannes
Аннотация
INTRODUCTION: Pulmonary embolism (PE) at initial diagnosis and during first-line systemic treatment is clinically relevant in patients with lung cancer. However, real-world incidence of subclinical PE is not well established.
METHODS: Retrospective single-center analysis of patients at least 18 years old with non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) who received first-line/induction systemic therapy. All patients underwent contrast-enhanced computed tomography (CT) of the thorax with bolus tracking for PE detection. Treatment response was assessed by restaging at weeks 6 and 12 after treatment initiation.
RESULTS: A total of 373 patients treated between 2019 and 2022 were included (261 NSCLC, 112 SCLC; 179 women and 194 men; median age 66 years [range, 22 to 86]; median smoking history 40 Pack Years [range, 0-150]). There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n = 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.PE was detected in 61/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p = 0.005), while central tumor localization (OR 5.637, p = 0.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC. All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.
CONCLUSION: This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.
METHODS: Retrospective single-center analysis of patients at least 18 years old with non-small-cell lung cancer (NSCLC) or small-cell lung cancer (SCLC) who received first-line/induction systemic therapy. All patients underwent contrast-enhanced computed tomography (CT) of the thorax with bolus tracking for PE detection. Treatment response was assessed by restaging at weeks 6 and 12 after treatment initiation.
RESULTS: A total of 373 patients treated between 2019 and 2022 were included (261 NSCLC, 112 SCLC; 179 women and 194 men; median age 66 years [range, 22 to 86]; median smoking history 40 Pack Years [range, 0-150]). There was a predominance of locally advanced and metastatic disease (IB-IIB, n = 22; IIIA-C, n = 123; IVA-B, n = 228). Adenocarcinoma was the predominant histology among NSCLC cases (LUAD, n = 146), followed by squamous cell carcinoma and other NSCLC subtypes combined (n = 115); 112 patients had SCLC.PE was detected in 61/373 patients, of whom 58 (95%) had subclinical PE. In NSCLC, body-mass-index (BMI) was independently associated with occurrence of PE (OR = 1.111, p = 0.005), while central tumor localization (OR 5.637, p = 0.028) and vascular infiltration (OR 7.683, p = 0.010) were significantly associated with PE in SCLC. All patients with PE received anticoagulants according to national and international guidelines and no PE-related deaths occurred.
CONCLUSION: This single-center analysis demonstrates a high incidence of subclinical PE in newly diagnosed lung cancer patients and identifies clinical risk factors associated with PE development.